SEC Form 10-Q filed by Apellis Pharmaceuticals Inc.
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $36.00 | Buy → Neutral | Goldman |
| 11/21/2024 | $31.00 | Equal-Weight | Morgan Stanley |
| 10/25/2024 | $25.00 | Sector Perform | RBC Capital Mkts |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/16/2024 | Outperform | William Blair | |
| 5/31/2024 | $46.00 | Neutral | Piper Sandler |
| 2/5/2024 | $68.00 → $80.00 | Hold → Buy | Jefferies |
| 12/14/2023 | Overweight → Equal Weight | Wells Fargo |
Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net product revenues, including $23 million in 4Q 2024 Expects submission of EMPAVELI sNDA for C3G and primary IC-MPGN in early 2025; U.S. launch anticipated in 2H 2025, if approvedPlans initiation of Phase 3 studies of pegcetacoplan in two additional nephrology indications in 2H 2025Adam Townsend, chief operating officer, to depart Apellis in February; David Acheson named executive vice president of commercialMaintained strong financial position with year-end cash of approximately $410 million; proj
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. "We are delighted to welcome Keli to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Keli has a proven track record of successfully bringing novel medicines to patients as well as a respected reputation among industry leaders for her strategic thinking and innovation. Her deep commercial expertise will be invaluable as we c
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to one new employee with a grant date of January 2, 2025, as equity inducement awards outside of the company's 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received 4,135 restricted stock units (RSUs). Each RSU will vest as to 25% of the shares underlying
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity
144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
144 - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
Goldman downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $36.00
Morgan Stanley initiated coverage of Apellis Pharmaceuticals with a rating of Equal-Weight and set a new price target of $31.00
RBC Capital Mkts initiated coverage of Apellis Pharmaceuticals with a rating of Sector Perform and set a new price target of $25.00
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue of $152.0 million Increase in demand offset by higher gross-to-net adjustments in the quarter Following FDA feedback, on track to file an sNDA seeking approval of pegcetacoplan for C3G / primary IC-MPGN in early 2025 based on positive 6-month Phase 3 VALIANT results Cash and cash equivalents of $396.9 million as of September 30, 2024; projected revenues and cash expected to be sufficient to fund operations to positive cash flow Management to host conference call today at 8:30 a.m. ET
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2024 financial results on Tuesday, November 5, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines
Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study populationPositive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneysDemonstrated favorable safety, consistent with established profileCompanies plan to submit data for regulatory approval in the US and EU Apellis to host a conference call today at 8:00 a.m. ET WALTHAM, Mass. and STOCKHOLM, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and Sobi® (STO: SOBI) today announced positive topline results from the Phase 3 VALIANT study investi
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more than two decades of biopharmaceutical commercial leadership experience to the Board. "We are delighted to welcome Keli to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Keli has a proven track record of successfully bringing novel medicines to patients as well as a respected reputation among industry leaders for her strategic thinking and innovation. Her deep commercial expertise will be invaluable as we c
WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that leading retina specialist Philip Ferrone, M.D., will join the company as Chief Medical Retina Advisor, effective March 18. "Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Retina Specialists (ASRS), so we are delighted to welcome him to the Apellis team," said Caroline Baumal, M.D., Chief Medical Officer, Apellis. "Phil has extensive expertise in retina research and patient care, which will be invaluable as we continue to bring SYFOVRE to patients with GA and advance our retina pipeline." "It is an honor to jo
WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replaces Federico Grossi, M.D., Ph.D., who plans to remain at Apellis until February 28, 2023 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy (GA). "Caroline is a world-renowned retina specialist who has been at the forefront of retina research and patient care for over 25 years, and we are thrilled to welcome her to Apellis," said Cedric Francois, M.
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)